Cyclerion Therapeutics Inc (CYCN) Stock Price, Quote & News

Company Profile

Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 327 8778

Website: www.cyclerion.com

Address:

245 First Street, Riverview II, 18th Floor, Cambridge, United States

littleimagination Sep. 17 at 2:52 PM

$CYCN Krsa loks good here but RGC could rocket to the moon

0 · Reply

Aatrader2475 Sep. 13 at 10:33 PM

$CYCN isn’t this trading under KRSA now?

1 · Reply

simplifocused Sep. 12 at 8:02 PM

$CYCN It's UBS price target raised. NFA

0 · Reply

simplifocused Sep. 11 at 11:28 PM

$CYCN UBA buyout at $55 a share NFA

0 · Reply

ShadowSnake Sep. 10 at 4:45 PM

$CYCN I had no clue the merger included a reverse split… glad I took the loss before this mess.. wow

1 · Reply

TwongStocks Sep. 9 at 8:35 PM

Today's reverse split results. $ALP 1 for 50 Previous close $0.1077, $5.385 split-adjusted Today's high $5.78 Today's close $5.4141 🟢Up 0.54% $KRSA (formerly $CYCN) 1 for 7 Previous close $3.36, $23.52 split-adjusted Today's high $26.20 Today's close $26.20 🟢Up 11.39% $UCAR 1 for 20 Previous close $0.4328, $8.656 split-adjusted Today's high $8.99 Today's close $8.36 🔴Down 3.42%

0 · Reply

YouVSYou Sep. 9 at 7:45 PM

$UCAR Interesting off $SUNE with $CYCN $BRTX $GTBP

0 · Reply

lob11 Sep. 9 at 7:41 PM

$CYCN This stock is a bagholder creator.

0 · Reply

Leafy4 Sep. 9 at 4:25 PM

$CYCN new ticker is krsa

0 · Reply

Flowjob Sep. 9 at 1:51 PM

$CYCN Looks like almost a billion market cap 16.83M float

0 · Reply

Korsana Biosciences Completes Closing of Merger with Cyclerion Therapeutics and Previously Announced Private Placement of $380 Million

Apr 1, 2026, 7:05 AM EDT - 5 months ago

Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Feb 17, 2026, 7:00 AM EST - 7 months ago

Cyclerion Therapeutics Announces Progress Toward CYC-126 Phase 2 Proof-of-Concept Study with FDA Feedback and Formation of Clinical Advisory Board

Jan 5, 2026, 4:01 PM EST - 8 months ago

Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression

Sep 23, 2025, 4:01 PM EDT - 12 months ago

Cyclerion Announces Transformational Relaunch as a Neuropsychiatric Company

Dec 17, 2024, 8:08 AM EST - 1 year ago

Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

Aug 7, 2024, 7:00 AM EDT - 2 years ago

Regina Graul, Ph.D., Promoted to Chief Executive Officer

Dec 4, 2023, 8:00 AM EST - 2 years ago

Cyclerion Appoints Regina Graul, Ph.D., as President

Nov 30, 2023, 6:16 PM EST - 2 years ago

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

Jul 31, 2023, 7:00 AM EDT - 3 years ago

Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets

Jun 1, 2023, 4:00 PM EDT - 3 years ago

Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 15, 2023, 1:00 PM EDT - 3 years ago

Cyclerion Announces Reverse Stock Split

May 11, 2023, 6:00 PM EDT - 3 years ago

Cyclerion Announces Definitive Agreement for Zagociguat and CY3018

May 11, 2023, 6:00 PM EDT - 3 years ago

Cyclerion Announces Corporate Updates and Q1 2023 Financial Results

Apr 3, 2023, 7:30 AM EDT - 3 years ago

Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement

Mar 27, 2023, 7:00 AM EDT - 3 years ago

Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases

Mar 22, 2023, 4:40 PM EDT - 3 years ago

Cyclerion Reports Corporate Update and Full Year 2022 Financial Results

Nov 22, 2022, 7:00 AM EST - 3 years ago

Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company

Oct 6, 2022, 8:00 AM EDT - 3 years ago

Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy

Aug 9, 2022, 4:00 PM EDT - 4 years ago

Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results

Jul 28, 2022, 7:00 AM EDT - 4 years ago

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)

Jul 26, 2022, 7:00 AM EDT - 4 years ago

Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics' Board of Directors

Jun 28, 2022, 9:00 AM EDT - 4 years ago

Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Jun 22, 2022, 8:30 AM EDT - 4 years ago

Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Jun 17, 2022, 8:00 AM EDT - 4 years ago

Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease

Jun 10, 2022, 7:00 AM EDT - 4 years ago

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium

Jun 6, 2022, 7:00 AM EDT - 4 years ago

Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium

May 4, 2022, 4:01 PM EDT - 4 years ago

Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results

Feb 24, 2022, 4:01 PM EST - 4 years ago

Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates

Feb 23, 2022, 8:00 AM EST - 4 years ago

Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration

Jan 26, 2022, 8:00 AM EST - 4 years ago

Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer's Disease with Vascular Pathology

Nov 11, 2021, 5:32 PM EST - 4 years ago

Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference

Nov 9, 2021, 4:01 PM EST - 4 years ago

Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update

Sep 22, 2021, 8:00 AM EDT - 4 years ago

Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator

Aug 23, 2021, 5:00 PM EDT - 5 years ago

Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer's Disease Summit

Jul 29, 2021, 5:00 PM EDT - 5 years ago

Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update

Jul 22, 2021, 4:30 PM EDT - 5 years ago

Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer's Disease with Vascular Pathology at the Alzheimer's Association International Conference 2021 (AAIC)

Jul 8, 2021, 7:22 PM EDT - 5 years ago

Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership

Jul 8, 2021, 4:30 PM EDT - 5 years ago

Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership

Jun 4, 2021, 8:00 AM EDT - 5 years ago

Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat

Jun 4, 2021, 8:00 AM EDT - 5 years ago

Cyclerion Therapeutics Announces $18 Million Private Placement

May 27, 2021, 4:30 PM EDT - 5 years ago

Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology

May 25, 2021, 7:00 AM EDT - 5 years ago

Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference

Apr 27, 2021, 9:00 AM EDT - 5 years ago

Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress

Apr 26, 2021, 7:00 AM EDT - 5 years ago

Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors

Apr 21, 2021, 7:30 AM EDT - 5 years ago

Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference

Apr 20, 2021, 7:00 AM EDT - 5 years ago

Cyclerion Therapeutics to Host Pipeline Update Webinar

Mar 18, 2021, 5:00 PM EDT - 5 years ago

Cyclerion Therapeutics Announces Departure of Chief Medical Officer

littleimagination Sep. 17 at 2:52 PM

$CYCN Krsa loks good here but RGC could rocket to the moon

0 · Reply

Aatrader2475 Sep. 13 at 10:33 PM

$CYCN isn’t this trading under KRSA now?

1 · Reply

simplifocused Sep. 12 at 8:02 PM

$CYCN It's UBS price target raised. NFA

0 · Reply

simplifocused Sep. 11 at 11:28 PM

$CYCN UBA buyout at $55 a share NFA

0 · Reply

ShadowSnake Sep. 10 at 4:45 PM

$CYCN I had no clue the merger included a reverse split… glad I took the loss before this mess.. wow

1 · Reply

TwongStocks Sep. 9 at 8:35 PM

0 · Reply

YouVSYou Sep. 9 at 7:45 PM

$UCAR Interesting off $SUNE with $CYCN $BRTX $GTBP

0 · Reply

lob11 Sep. 9 at 7:41 PM

$CYCN This stock is a bagholder creator.

0 · Reply

Leafy4 Sep. 9 at 4:25 PM

$CYCN new ticker is krsa

0 · Reply

Flowjob Sep. 9 at 1:51 PM

$CYCN Looks like almost a billion market cap 16.83M float

0 · Reply

Buyitall2024 Sep. 9 at 1:27 PM

$CYCN what’s the float?

1 · Reply

TwongStocks Sep. 9 at 12:16 PM

$CYCN NASADQ updated their halt status. Ticker CYCN has been deleted. Ticker KRSA will begin trading at 9:00am ET.

0 · Reply

TwongStocks Sep. 9 at 10:40 AM

$ALP $CYCN $UCAR All three with reverse splits today. Trading resumes at 9:00am ET, with the RS in effect. NOTE: No trading time posted yet for CYCN. I assume that it will start trading at 9am ET, under the new ticker KRSA.

0 · Reply

FreeBeerTomorrow Sep. 9 at 7:26 AM

$CYCN * Cyclerion Therapeutics (CYCN) is executing a 1-for-7 reverse stock split today, Wednesday, September 9, 2026. Post-Split Estimated Float/Outstanding Shares: ~700,000.

0 · Reply

CEMBP_Trader Sep. 8 at 11:18 PM

$CYCN In the CVR club 🎉🍀🎉

1 · Reply

skyrockets_Inc Sep. 8 at 9:19 PM

$CYCN I received my CVRs today in 2 of my 3 brokerage accounts. Robinhood and Schwab . Etrade CVRs havent shown up yet.

1 · Reply

TwongStocks Sep. 8 at 8:13 PM

Three NASDAQ stocks with reverse splits on Wednesday. Expect trading to halt at 7:50pm ET tonight and resume at 9:00am Wednesday morning. $ALP 1 for 50. Will reduce outstanding shares from approx 77.49m to approx 1.55m. $CYCN 1 for 7. The reverse split is in conjunction with their merger with Korsana Biosciences. After the RS and merger, CYCN will begin trading as Korsana Biosciences $KRSA. $UCAR 1 for 20. Will reduce outstanding shares from approx 35.46m to approx 1.77m.

0 · Reply

skyrockets_Inc Sep. 8 at 2:16 PM

$CYCN #1 and #2 below currently in action.

0 · Reply

TwongStocks Sep. 4 at 6:44 PM

$CYCN Equity Corporate Actions Alert #2026 - 648 Information Regarding the Business Combination, Change of Control, and Reverse Split of Cyclerion Therapeutics, Inc. (CYCN) & Korsana Biosciences, Inc. https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-648 The business combination of Cyclerion Therapeutics, Inc. (CYCN) & Korsana Biosciences, Inc. resulting in a Change of Control is expected to close on September 8, 2026. As a result, Cyclerion Therapeutics, Inc. (CYCN) will undergo a one-for-seven (1-7) reverse stock split of its Common Stock along with a change of name, symbol & Cusip. Further, participating holders of record on September 4, 2026 will receive one (1) Contingent Value Right (CVR) for each share held. The CVR distribution will not be quoted EX. These changes are expected to become effective on Wednesday, September 9, 2026. Subject to closing. Following the RS and merger, CYCN will begin trading under the ticker $KRSA Korsana Biosciences, Inc.

0 · Reply

YouVSYou Sep. 4 at 6:33 PM

$GRI 64% now off the Sunday watchlist $OSTX $CYCN worked Waiting on $LGVN $QTTB Juicy 🧃

0 · Reply

skyrockets_Inc Sep. 4 at 5:49 PM

$CMMB After my $CYCN merger is complete next week I'll be buying 25-50k more $CMMB, likely Tuesday or Wednesday at the latest. You have been warned.....AGAIN lol Currently holding 250k shares at ~$2.40 / share avg.

1 · Reply

joe77w Sep. 4 at 12:58 PM

$CYCN buying today gives right to CVR or not? Pps falling down as today would be ex dividend...

1 · Reply

Market Cap	15.73M
Revenue (ttm)	2.07M
Net Income (ttm)	-3.53M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-170.53%
Debt to Equity Ratio	0.00

Volume	437,400
Avg Vol	50,232
Day's Range	N/A - N/A
Shares Out	4.68M
Stochastic %K	23%
Beta	1.75
Analysts	Strong Buy
Price Target	$8.00